TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23810271
Drug: 4% aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% aqueous solution (Xylocaine™)
Study: 23774308
Drug: Submucosal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Submucosal administration of 300 U onabotulinumtoxinA (onaBoNT/A)
Study: 23774308
Drug: Detrusor administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Detrusor administration of 300 U onabotulinumtoxinA (onaBoNT/A)
Study: 23774308
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of submucosal vs detrusor administration
Study: 19242624
Drug: Orthopaedic manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthopaedic manual therapy
Study: 16983840
Drug: i.v. dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. dexamethasone 0.5 mg/kg
Study: 9411419
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with anti thyroglobulin antibodies (ATG)
Study: 9411419
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with anti thyroid microsomal antibodies (MAB)
Study: 2891536
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg ranitidine
Study: 2567580
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ranitidine
Study: 6130952
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg cimetidine
Study: 30793466
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (halved doses of valsartan and benazepril)
Study: 22357964
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro salicylate treatment
Study: 20378005
Drug: NiOH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NiOH treatment
Study: 10488254
Drug: Bier block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bier block solution with 2 mg of morphine sulfate
Study: 7659265
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg die
Study: 7659265
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg die
Study: 2504119
Drug: Flecainide (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flecainide (0.15 mg/kg/h after a loading dose of 2 mg/kg)
Study: 18543484
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository
Study: 10753983
Drug: Adjusted-dose warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted-dose warfarin (INR 2.0 to 3.0)
Study: 14725326
Drug: 5-FU (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU (1% cream)
Study: 10890481
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion plus transesophageal atrial pacing (group 2, 17 patients)
Study: 10890481
Drug: Phenylephrine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine infusion (group 1, 19 patients)
Study: 6422538
Drug: Cimetidine, 200
Normalized name: Cimetidine, 200 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 200 mg four times daily
Study: 373071
Drug: Cimetidine, 400
Normalized name: Cimetidine, 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine, 400 mg twice daily
Study: 6422538
Drug: Oxmetidine, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxmetidine, 400 mg twice daily
Study: 28125093
Drug: Untreated group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Untreated group (no L-T4 supplementation)
Study: 10754619
Drug: Rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 1.5 mg/kg
Study: 10754619
Drug: Rapacuronium 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 2.0 mg/kg
Study: 24973911
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (CC) program for treating depression following CABG surgery
Study: 17986908
Drug: Health Education
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Education Control (SA) consisting of weekly workshops transitioning to monthly
Study: 16617391
Drug: (123)I‐ioflupane administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: (123)I‐ioflupane administration (110‐185 MBq/70 kg); thyroid blocking with 120 mg potassium iodide before and after injection.
Study: 14551174
Drug: eplerenone 50
Normalized name: eplerenone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: eplerenone 50 mg qd (increased to 100 mg qd if needed)
Study: 8793612
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg plus hydrochlorothiazide 25 mg (CAP, n = 24)
Study: 6791487
Drug: Verapamil 360
Normalized name: verapamil 360 mg/24 hours oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 360 mg daily
Study: 31945300
Drug: Isoniazid 5
Normalized name: isoniazid 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoniazid 5 mg/kg daily for 7 days
Study: 22483675
Drug: Dose-escalation to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation to the entire primary tumour (arm A)
Study: 22483675
Drug: Dose-escalation to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation to the primary tumour (arm A)
Study: 22483675
Drug: Dose-escalation to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation to the high FDG uptake region inside the primary tumour (arm B)
Study: 22483675
Drug: Dose-escalation to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalation to the boost region
Study: 20211036
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of enteral nutrition (EN) with parenteral nutrition (PN)
Study: 20211036
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (PN) alone
Study: 18540460
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with crystalloidal solutions
Study: 18540460
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of crystalloidal solutions and a colloidal agent in a 1:1 ratio
Study: 18540460
Drug: Infusion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion therapy with physiological sodium chloride
Study: 12125943
Drug: Combination ointment
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination ointment (calcipotriol/betamethasone dipropionate)
Study: 16911387
Drug: Ointment vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment vehicle
Study: 8540720
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine twice a day
Study: 8540720
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine twice a day
Study: 1780078
Drug: Heparan sulfate
Normalized name: heparan sulfate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparan sulfate (200 mg/die, 1 tablet in the morning and evening)
Study: 6112387
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 81 mg aspirin taken 14 h preoperatively
Study: 6112387
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 40 mg aspirin taken 14 h preoperatively
Study: 6112387
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 300 mg aspirin
Study: 6112387
Drug: A single
Normalized name: Hemoccult Sensa Single Slide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 40 mg aspirin
Study: 28402747
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg orally
Study: 28402747
Drug: Paclitaxel (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (80 mg/m2 days 1, 8, and 15 every 28 days)
Study: 23175270
Drug: Conventional cytology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional cytology (CC)
Study: 21047620
Drug: Individually-tailored Internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually-tailored Internet-based treatment for anxiety disorders over 10 weeks with online therapist guidance.
Study: 8800399
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg/day)
Study: 3917315
Drug: Methimazole 30
Normalized name: Methimazole
DrugBank: Methimazole (DB00763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methimazole 30 mg + thyroxine 0.15 mg daily
Study: 31513248
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of adjuvant oxaliplatin-based chemotherapy
Study: 29849515
Drug: Community-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based occupational therapy program (6 weeks)
Study: 26528636
Drug: Baseline galectin‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline galectin‐3 (≥17.8ng/mL)
Study: 26528636
Drug: Baseline sST2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline sST2 (≥35.0ng/mL)
Study: 15206646
Drug: Latanoprost 0.005%
Normalized name: LATANOPROST 0.005% SOLN,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost 0.005% once daily
Study: 15036568
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice daily
Study: 7875811
Drug: Intraosseous (IO)
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraosseous (IO) route for fluid infusion
Study: 7875811
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) route for fluid infusion
Study: 3345044
Drug: Oral sustained-release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sustained-release theophylline
Study: 30968604
Drug: Cisplatin-paclitaxel (Cisplatin-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin-paclitaxel (Cisplatin-20 mg/m2; Paclitaxel-30 mg/m2 qw x 7)
Study: 25387260
Drug: Weekly testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly testosterone administration (100 mg T enanthate, im injection, n = 5)
Study: 25387260
Drug: Monthly testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monthly testosterone administration (alternating months of T and placebo, n = 7)
Study: 26535126
Drug: Naloxegol 25
Normalized name: naloxegol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 25 mg
Study: 24238792
Drug: Naloxegol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxegol 150 mg
Study: 15673998
Drug: Self-selected homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-selected homeopathic medicine
Study: 15673998
Drug: Treatment by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment by homeopaths
Study: 31302851
Drug: Guanxinning Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanxinning Tablet (GXN), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Study: 31302851
Drug: Placebo (Guanxinning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Guanxinning simulation tablets, mainly composed of lactose), 4 tablets (0.38 g/tablet), thrice daily for 12 weeks
Study: 30051690
Drug: Mindfulness-based group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based group training (8 sessions of 90 minutes each, twice a week for 1 month)
Study: 26999528
Drug: Zero-profile implant
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zero-profile implant (Zero-P)
Study: 20187135
Drug: Combination etanercept-methotrexate
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination etanercept-methotrexate therapy (EM/EM group, n = 111)
Study: 20187135
Drug: Etanercept monotherapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept monotherapy (EM/E group, n = 111)
Study: 20187135
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (M/EM group, n = 90)
Study: 20187135
Drug: Combination etanercept-methotrexate
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination etanercept-methotrexate therapy (EM/EM group)
Study: 20187135
Drug: Etanercept monotherapy
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept monotherapy (EM/E group)
Study: 18576924
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral administration of C. aurantium L. extracts and auricular acupressure
Study: 7863967
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone or Warfarin alone
Study: 1645768
Drug: Lisinopril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-40 mg once a day)
Study: 1645768
Drug: Captopril (25-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25-100 mg twice a day)
Study: 26953758
Drug: 4-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day antibiotic therapy (n = 72)
Study: 23253201
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment condition (control group).
Study: 9527071
Drug: Ongoing daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ongoing daily therapy of 50 mg aspirin and 400 mg dipyridamole
Study: 2214100
Drug: Intrapleural instillation
Normalized name: Talc Powder for intrapleural instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural instillation of 1500 mg of tetracycline hydrochloride
Study: 22336901
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Group A)
Study: 22773165
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg JNJ-37822681 (twice daily for 13 doses)
Study: 22773165
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of JNJ-37822681
Study: 11294130
Drug: Fibre supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement (initial dose of 6 g and maintenance dose of 4 g)
Study: 11294130
Drug: Fibre supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement and reduced energy intake
Study: 8872406
Drug: Lidocaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (3 mg/kg i.v.) with liminal stimulation (C)
Study: 8872406
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups after completed series of treatments
Study: 8872406
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups after four treatments
Study: 1379054
Drug: Loratadine 10
Normalized name: loratadine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine 10 mg once a day for 5 days
Study: 30582246
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (SS) (control)
Study: 23584593
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA 1 g/day
Study: 19574865
Drug: Extended-release epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release epidural morphine (EREM) groups (with/without prior bupivacaine)
Study: 19574865
Drug: Bupivacaine +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine + placebo (normal saline) administered 15, 30, or 60 mins after bupivacaine
Study: 15121929
Drug: Prophylactic application
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic application of emollient ointment twice a day through day 14 (P)
Study: 8075441
Drug: 0.5% podophyllotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% podophyllotoxin cream
Study: 8003791
Drug: 0.3% and
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% and 0.5% podophyllotoxin creams
Study: 2523681
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nebulized solution 0.4 mg
Study: 2523681
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide nebulized solution 0.4 mg and 0.6 mg
Study: 304691
Drug: Kallikrein inhibitor
Normalized name: Kallikrein inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kallikrein inhibitor (protease-inhibitor)
Study: 304691
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no kallikrein inhibitor)
Study: 17189867
Drug: Rosiglitazone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone + Insulin
Study: 15108771
Drug: Standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus (trough levels of 10-15 ng/mL) plus reduced sirolimus (trough levels of 5-10 ng/mL) (Group I)
Study: 7506878
Drug: Aspartame (APM)
Normalized name: Aspartame
DrugBank: Aspartame (DB00168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspartame (APM) 34 mg/kg single morning dose
Study: 6627697
Drug: Morphine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (10 mg)
Study: 22298375
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (negative control)
Study: 21267525
Drug: n‐3 LCPUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 LCPUFA supplementation (2.5 g/day, with 1.67 grams of EPA and 0.83 grams of DHA)
Study: 17941876
Drug: Nateglinide +
Normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nateglinide + Metformin
Study: 3911096
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg guanfacine hydrochloride (Estulic)
Study: 3911096
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg guanfacine hydrochloride (Estulic)
Study: 3911096
Drug: 0.15 mg
Normalized name: iodine 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg clonidine (Catapres)
Study: 3911096
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg clonidine (Catapres)
Study: 29505517
Drug: Control (fasting,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (fasting, decompression, intravenous somatostatin)
Study: 26909012
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment with ibuprofen
Study: 788655
Drug: Non-antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-antibiotic treatment
Study: 1978612
Drug: Esmolol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1.5 mg/kg
Study: 9084524
Drug: Esmolol 2
Normalized name: esmolol 20 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 2 mg/kg
Study: 19273696
Drug: INT0116 (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: INT0116 (standard treatment)
Study: 8316346
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 450-750 mg/day
Study: 27958690
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF) 300 µg, two injections prior to BM-MNC transplantation
Study: 26149149
Drug: Short-term pressure
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term pressure gauge training (G group)
Study: 19260323
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment
Study: 22352262
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid plus basic treatment
Study: 7051246
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ; 160 mg of TMP and 800 mg of SMZ) twice daily for 21 days
Study: 21915572
Drug: PTH 1-84
Normalized name: PTH(1-84)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH 1-84 (100 µg once daily)
Study: 14687899
Drug: No-drug treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-drug treatment
Study: 18287591
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (1 mg)
Study: 6134490
Drug: Alclofenac 1
Normalized name: Acéclofénac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alclofenac 1 g 3 or 4 times daily
Study: 6134490
Drug: Gold injections
DrugBank: Gold (DB14154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold injections 50 mg weekly intramuscularly to 1 g then 50 mg monthly
Study: 29350663
Drug: Tailored medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored medical support including translated booklets, weekly visits, family-guides, and interpreter-supported clinic visits (Group 1)